Auditing the pharmacological accounts for Hsp90 molecular chaperone inhibitors: unfolding the relationship between pharmacokinetics and pharmacodynamics.
Workman
Paul
P
Cancer Research UK Centre for Cancer Therapeutics, Institute of Cancer Research, Sutton, Surrey SN2 5NG, United Kingdom. paulw@icr.ac.uk
D016227:Benzoquinones; D004791:Enzyme Inhibitors / Q000493:pharmacokinetics / Q000494:pharmacology; D015972:Gene Expression Regulation, Neoplastic; D018841:HSP90 Heat-Shock Proteins / Q000037:antagonists & inhibitors*; D006801:Humans; D047029:Lactams, Macrocyclic; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism*; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors; D017828:Rifabutin / Q000031:analogs & derivatives* / Q000493:pharmacokinetics* / Q000494:pharmacology*
D016227:Benzoquinones; D004791:Enzyme Inhibitors; D018841:HSP90 Heat-Shock Proteins; D047029:Lactams, Macrocyclic; D017828:Rifabutin; C112765:tanespimycin; D017346:Protein Serine-Threonine Kinases